The same group of neurology experts narrowly voted against the drug in March, due to concerns about missing data and implementation errors in the company’s study.
ABC 10 Sacramento's own description from its feed. We collect headlines and these descriptions, not full articles; read the original reporting below.
Developments in this update
2 dated developments, oldest first, newest marked. Each is named by one outlet's own headline; open its reports to see every outlet that covered it.
Names this update
FDA panel backs much-debated ALS drug in rare, 2nd review
A closely watched experimental drug for Lou Gehrig's disease got an unusual second look from U.S. regulators on Wednesday, following intense pressure to approve the treatment for those with the fatal illness.
The same group of neurology experts narrowly voted against the drug in March, due to concerns about missing data and implementation errors in the company’s study.
A panel of federal health advisers voted Wednesday to recommend approval for an experimental drug to treat Lou Gehrig’s disease, a remarkable turnaround for the much-debated medication that was previously rejected by the same group.
TUESDAY, Sept. 6, 2022 (HealthDay News) -- A U.S. Food and Drug Administration panel will once again consider approval for an experimental drug for amyotrophic lateral sclerosis (ALS), a rare
A panel of federal health advisers voted Wednesday to recommend approval for an experimental drug to treat Lou Gehrig’s disease, a remarkable turnaround for the much-debated medication that was previously rejected by the same group.
An FDA advisory panel voted Wednesday to recommend approval for a highly-debated amyotrophic lateral sclerosis drug. Only two therapies are currently approved,
THURSDAY, Sept. 8, 2022 (HealthDay News) – In a rare second review, a U.S. Food and Drug Administration panel on Wednesday recommended approval for an experimental drug for ALS (amyotrophic
In a remarkable turnaround, a panel of federal health advisers has voted to recommend approval for an experimental drug to treat Lou Gehrig's disease. Patients and their families have rallied behind Amylyx's drug, urging approval.
